{
  "ticker": "LGP",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02970107",
  "id": "02970107",
  "pages": 16,
  "price_sensitive": true,
  "date": "20250717",
  "time": "0928",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250717/pdf/06lwb9gvq8p9j2.pdf",
  "summary": "### **Little Green Pharma \u2013 Quarterly Activities Report & Appendix 4C (June 2025)**  \n\n#### **Financial Highlights**  \n- **Revenue**: $9.1M (unaudited, +20% YoY)  \n- **Cash receipts**: $12.0M (+50% YoY)  \n- **Operating cashflow**: $0.5M inflow (vs. prior $0.75M outflow)  \n- **Closing cash balance**: $2.5M (up from $2.4M last quarter)  \n- **Unused financing facilities**: $5.0M available  \n\n#### **Operational Highlights**  \n- **Capacity expansion**: Danish facility now at 8.5tpa (+2.4tpa commissioned; additional 2.4tpa room in progress).  \n- **Germany sales**: +70% growth from Danish facility; CherryCo brand launched post-quarter.  \n- **UK market**: $2M+ purchase orders received for FY26Q2/Q3.  \n- **Regulatory**: Danish laws (effective Jan 2026) enable import/distribution hub status.  \n\n#### **Valuation & Capital Structure**  \n- **Net Tangible Assets (NTA)**: $0.24/share  \n- **Enterprise Value**: 0.8x revenue, 0.4x NTA.  \n\n#### **Additional Notes**  \n- **Appendix 4C Key Items**:  \n  - **Payments to related parties**: $0.42M (incl. $0.14M FY24 STI).  \n  - **No material debt raised or repaid during quarter**.  \n\n**No material capital markets actions (e.g., raising, halt) identified.**",
  "usage": {
    "prompt_tokens": 5646,
    "completion_tokens": 354,
    "total_tokens": 6000,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-16T23:45:21.542482"
}